1,620
Views
13
CrossRef citations to date
0
Altmetric
Original Research

A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI

, , , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Chitra Lal & Charlie Strange. (2019) Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 20:9, pages 1075-1085.
Read now
Antonio Molino, Giovanna Calabrese & Mauro Maniscalco. (2018) Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Preference and Adherence 12, pages 993-1001.
Read now
Timothy E Albertson, Samuel W Bullick, Michael Schivo & Mark E Sutter. (2016) Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Design, Development and Therapy 10, pages 4047-4060.
Read now

Articles from other publishers (10)

Yuqing Ye, Ying Ma & Jesse Zhu. (2022) The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?. International Journal of Pharmaceutics 614, pages 121457.
Crossref
Mohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. MadneyMohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. Madney. 2021. Essentials of Aerosol Therapy in Critically ill Patients. Essentials of Aerosol Therapy in Critically ill Patients 89 114 .
Mohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. MadneyMohamed E. A. Abdelrahim, Haitham Saeed, Hadeer S. Harb & Yasmin M. Madney. 2021. Essentials of Aerosol Therapy in Critically ill Patients. Essentials of Aerosol Therapy in Critically ill Patients 65 88 .
Haitham Saeed, Heba F. Salem, Hoda Rabea & Mohamed E. A. Abdelrahim. (2018) Effect of Human Error, Inhalation Flow, and Inhalation Volume on Dose Delivery from Ellipta® Dry-Powder Inhaler. Journal of Pharmaceutical Innovation 14:3, pages 239-244.
Crossref
Chaeho Moon, Hugh D. C. Smyth, Alan B. Watts & Robert O. WilliamsIIIIII. (2019) Delivery Technologies for Orally Inhaled Products: an Update. AAPS PharmSciTech 20:3.
Crossref
Hong-Goo Lee, Dong-Wook Kim & Chung-Woong Park. (2017) Dry powder inhaler for pulmonary drug delivery: human respiratory system, approved products and therapeutic equivalence guideline. Journal of Pharmaceutical Investigation 48:6, pages 603-616.
Crossref
Muhammad Suleman Khan & Michael S. Roberts. (2018) Challenges and innovations of drug delivery in older age. Advanced Drug Delivery Reviews 135, pages 3-38.
Crossref
Henrik Svedsater, Helen A. Doll, Jake Macey, Gail Miles, Lisa Bradshaw & Magdalena Vanya. (2018) Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences. Advances in Therapy 35:9, pages 1378-1399.
Crossref
Thomas L Jones, Daniel M Neville & Anoop J Chauhan. (2018) The Ellipta ® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability . Therapeutic Delivery 9:3, pages 169-176.
Crossref
Nicole Rockich-Winston, Chris Gillette, Brian Train, Amber S Tippens, Susan Flesher & Meagan Shepherd. (2016) A model to integrate patient preferences into delivery systems: the importance of end-user input into pulmonary delivery. Therapeutic Delivery 7:9, pages 591-593.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.